IDO-Independent Suppression of T Cell Effector Function by IFN-γ–Licensed Human Mesenchymal Stromal Cells
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Human bone marrow–derived mesenchymal stromal cells (MSCs) inhibit proliferation of activated T cells, and IFN-γ plays an important role in this process. This IFN-γ–licensed veto property is IDO-dependent. To further decipher the mechanistic underpinnings of MSC veto function on T cells, we investigated the effect of MSCs and IFN-γ–licensed MSCs on T cell effector function as assayed by cytokine secretion of T cells. Although MSCs and IFN-γ–licensed MSCs inhibit T cell proliferation, only IFN-γ–licensed MSCs significantly inhibit Th1 cytokine (IFN-γ, TNF-α, and IL-2) production by T cells. Additionally, IFN-γ–licensed MSCs inhibit T cell degranulation as well as single, double, and triple cytokine–producing T cells. Although IFN-γ–licensed MSCs upregulate their IDO activity, we found that MSC IDO catalytic function is dispensable with regard to MSC-driven inhibition of T cell effector function. Novel flow cytometry based functional screening of MSC-expressed, IFN-γ–licensed inhibitory molecules identified B7H1 and B7DC/PD1 pathways as essential effectors in blocking T cell function. Small interfering RNA–mediated blocking of B7H1 and B7DC reverses the inhibitory potential of IFN-γ–licensed MSCs on T cell effector function. Mechanistic analysis revealed that clustering of MHC and coinhibitory molecules are indispensable for the inhibitory effect of IFN-γ MSCs. Although exogenous IL-2 reverses B7H1-Ig–mediated inhibition of T cell proliferation, it does not affect the veto function of IFN-γ MSCs on both T cell proliferation and effector function. Our results reveal a new immunosuppressive property of IFN-γ–licensed MSCs that inhibits T cell effector function independent of IDO but through the ligands for PD1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study by Chinnadurai et al. elegantly showed that MSCs can inhibit PBMC proliferation through PD1/PD-L1 [48].”
In the citing paper
“IFN-γ-primed MSCs have demonstrated to block T cell proliferation in a dose-dependent manner and to abrogate the production of IFN-γ, IL-2 and TNF-α, three cytokines with a role in T cell-derived immune response [136].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [136]
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“M arrowmesenchymal stromal cells (MSCs) play a role in maintaining the hematopoietic niche, regulate marrow immune homeostasis, and can differentiate into bone, cartilage, and adipocytes as a mesenchymal progenitor pool (1, 2).”
BackgroundMesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746 · cited 1×
“The therapeutic potential of transfused MSCs has been demonstrated in animal models of experimental autoimmune encephalitis, diabetes, rheumatoid arthritis, myocardial infarction, acute lung injury, retinal degeneration, acute renal failure, and transplant rejection (9, 10).”
BackgroundDi Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226 · cited 1×
“Therefore, an analysis of MSC immune plasticity in response to exogenous IFN-g stimulation (6, 22) and how this serves as an immune checkpoint to T cell activity are of physiological and translational interest.”
MethodCentral Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067 · cited 1×
“Once naive T cells are exposed to an activation signal they proliferate, and a subset becomes effector T cells as manifested by cytokine secretion and degranulation, based on their memory status (23, 24).”
BackgroundLe Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734 · cited 1×
“In human phase II clinical trials, MSCs were shown to be effective in treating graft-versus-host disease (11), although study of an industrial MSC product in a phase III trial was negative (12–14).”
BackgroundFriedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970) · Cell Proliferation · doi:10.1111/j.1365-2184.1970.tb00347.x · Cited by 2,724 · cited 1×
“Although endogenous clonogenic marrow MSCs represent a small minority of all nucleated cells in marrow space, typically 1:100,000, these same cells possess a robust mitogenic potential when cultured ex vivo (3, 4).”
BackgroundThe Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundHeterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.
Friedenstein, A. J., Kv, P., KUROLESOVA, A. I., & Frolova, G. P. (1968) · PubMed · Cited by 1,921
HETEROTOPIC TRANSPLANTS OF BONE MARROW
FRIEDENSTEIN, A. J., PETRAKOVA, K. V., KUROLESOVA, A. I., & FROLOVA, G. P. (1968) · Transplantation · doi:10.1097/00007890-196803000-00009 · Cited by 1,699
Meisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004) · Blood · doi:10.1182/blood-2003-11-3909 · Cited by 1,646
Research works printed but not linked: 1
- Jeremias, 1998, TRAIL/Apo-2-ligand-induced apoptosis in human T cells, Eur. J. Immunol., 28, 143, 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3 · DOI · Paper page
Cited by
Items 101–200 of 267
Morioka, C., Komaki, M., Taki, A., Honda, I., Yokoyama, N., Iwasaki, K., Iseki, S., Morio, T., & Morita, I. (2017) · Inflammation and Regeneration · doi:10.1186/s41232-016-0032-3 · Cited by 44
“Another report suggested that the immunosuppressive properties of MSCs were augmented by IFN-γ-pretreatment in vitro [30].”
Takeshita, K., Motoike, S., Kajiya, M., Komatsu, N., Takewaki, M., Ouhara, K., Iwata, T., Takeda, K., Mizuno, N., Fujita, T., et al. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0550-1 · Cited by 40
“In addition, IFN-γ induced immunosuppressive property of MSCs through upregulating programmed cell death ligand 1 (PD-L1), which binds to programmed cell death 1 (PD-1) in immune cells to modulate their activation [29, 30].”
BackgroundMesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment
Saldanha‐Araújo, F., Garcez, E. M., Silva-Carvalho, A. É., & Carvalho, J. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01563 · Cited by 40
Gómez-Aristizábal, A., Kim, K.-P., & Viswanathan, S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147868 · Cited by 44
“Levels of IFNγ in the OA joint tend to be approximately 200-fold lower [33] than our experimental conditions; relatively high levels were chosen based on previous evidence for both MSCs [32] and MDMs [30,31], and to assess the MSC- and HA-mediated effects under simplified pro-inflammatory conditions.”
BackgroundHeřmánková, B., Zajícová, A., Javorková, E., Chudíčková, M., Trošan, P., Hájková, M., Krulová, M., & Holáň, V. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.09.017 · Cited by 39
Najar, M., Raicevic, G., André, T., Fayyad‐Kazan, H., Pieters, K., Bron, D., Toungouz, M., & Lagneaux, L. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2015.11.013 · Cited by 43
Salem, B., Miner, S., Hensel, N. F., Battiwalla, M., Keyvanfar, K., Stroncek, D. F., Gee, A. P., Hanley, P. J., Bollard, C. M., Ito, S., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.08.008 · Cited by 37
Guan, Q., Ezzati, P., Spicer, V., Krokhin, O. V., Wall, D. A., & Wilkins, J. A. (2017) · Clinical Proteomics · doi:10.1186/s12014-017-9161-1 · Cited by 40
The involving progress of MSCs based therapy in atherosclerosis
Lin, Y., Zhu, W. P., & Chen, X. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01728-1 · Cited by 41
“BMSC-mediated immunosuppression partially relies on the soluble immunosuppressive factors secreted by BMSCs including HGF, transforming growth factor beta (TGF-β), IFN-γ, nitric oxide (NO), interleukin-2 (IL-2), prostaglandin E2 (PGE2), indoleamine-2,3-dioxygenase (IDO), and IL-10 [12, 13], further regulated by the se…”
BackgroundInfluentialHodgson‐Garms, M., Moore, M., Martino, M. M., Kelly, K., & Frith, J. E. (2025) · npj Regenerative Medicine · doi:10.1038/s41536-024-00382-y · Cited by 50
Recent advances in understanding mesenchymal stromal cells
Rendra, E., Scaccia, E., & Bieback, K. (2020) · F1000Research · doi:10.12688/f1000research.21862.1 · Cited by 39
Aging of Stem and Progenitor Cells: Mechanisms, Impact on Therapeutic Potential, and Rejuvenation
Nurković, J., Volarević, V., Lako, M., Armstrong, L., Arsenijević, N., & Stojković, M. (2015) · Rejuvenation Research · doi:10.1089/rej.2015.1676 · Cited by 36
Omental adipose tissue is a more suitable source of canine Mesenchymal stem cells
Francisca Bahamondes, G., Flores, E., Cattaneo, G., Bruna, F., & Conget, P. A. (2017) · BMC Veterinary Research · doi:10.1186/s12917-017-1053-0 · Cited by 39
Cabeza, V. P., Hoogduijn, M. J., Kraaijeveld, R., Franquesa, M., Witte‐Bouma, J., Wolvius, E. B., Farrell, E., & Brama, P. A. J. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00142 · Cited by 31
“MSCs are also well known to express major histocompatibility complex (MHC) class I molecules on their surface, but to have a minimal expression of MHC class II (Le Blanc et al., 2003) and co-stimulatory molecules such as CD80 and CD86 (Chamberlain et al., 2007).”
BackgroundInfluentialCurrent therapeutic strategies for respiratory diseases using mesenchymal stem cells
Wang, M., Zhou, T., Zhang, Z., Liu, H., Zheng, Z., & Xie, H. (2021) · MedComm · doi:10.1002/mco2.74 · Cited by 35
LL-37 boosts immunosuppressive function of placenta-derived mesenchymal stromal cells
Bravo, M. O., Sangiorgi, B., Schiavinato, J. L. D. S., Carvalho, J. L., Covas, D. T., Panepucci, R. A., Neves, F. D. A. R., Franco, O. L., Pereira, R. W., & Saldanha‐Araújo, F. (2016) · Stem Cell Research & Therapy · doi:10.1186/s13287-016-0448-3 · Cited by 36
“not reproduced when human MSCs were INF-γ licensed and used to control T cell proliferation in vitro [9] and to control immune response in vivo [10].”
BackgroundSouidi, N., Stolk, M., Rudeck, J., Strunk, D., Schallmoser, K., Volk, H.-D., & Seifert, M. (2017) · Stem Cells · doi:10.1002/stem.2573 · Cited by 32
Stress responses in stromal cells and tumor homeostasis
Vitale, I., Manic, G., Galassi, C., & Galluzzi, L. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.004 · Cited by 34
Montesinos, J. J., López-García, L., Cortés-Morales, V. A., Arriaga‐Pizano, L., Valle‐Rios, R., Fajardo-Orduña, G. R., & Castro-Manrreza, M. E. (2020) · Journal of Immunology Research · doi:10.1155/2020/8839625 · Cited by 38
“Several studies have indicated the importance of an inflammatory environment with high concentrations of IFN-γfor BM-MSCs to carry out efficient immunoregulation [7, 17, 21, 38, 44, 45], and in almost all in vitro conditioning protocols, the effect of this cytokine has been analyzed.”
InfluentialBurnham, A. J., Foppiani, E. M., & Horwitz, E. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609277 · Cited by 35
“Inhibition of T cell effector function was instead mediated by B7H1 and B7DC/PD1 pathways (23).”
BackgroundEsquivel‐Ruiz, S., González‐Rodríguez, P., Lorente, J. A., Pérez‐Vizcaíno, F., Herrero, R., & Moreno, L. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.752287 · Cited by 33
Mesenchymal stromal cells inhibit proliferation of virus-specific CD8+ T cells
Malcherek, G., Jin, N., Hückelhoven, A. G., Mani, J., Wang, L., Gern, U., Diehlmann, A., Wuchter, P., Schmitt, A., Chen, B., et al. (2014) · Leukemia · doi:10.1038/leu.2014.273 · Cited by 33
From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations
Refaie, A. F., Elbassiouny, B. L., Kloc, M., Sabek, O. M., Khater, S. M., Ismail, A. M., Mohamed, R. H., & Ghoneim, M. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.690623 · Cited by 35
Moeinabadi‐Bidgoli, K., Mazloomnejad, R., Maal, A. B., Aghdaei, H. A., Arki, M. K., Hossein‐Khannazer, N., & Vosough, M. (2023) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2023.2205017 · Cited by 38
Abreu, S. C., Hampton, T. H., Hoffman, E. T., Dearborn, J. S., Ashare, A., Sidhu, K. S., Matthews, D. E., McKenna, D. H., Amiel, E., Barua, J., et al. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00218.2020 · Cited by 32
“These are relevant findings, as IFN-c-mediated hMSC activation is well recognized in other systems and has been extensively investigated for priming MSCs (7, 22, 50).”
BackgroundBui, T. V. A., Hwang, J., Lee, J., Park, H., & Ban, K. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2020.0518 · Cited by 31
Mesenchymal Stem Cells and Myeloid Derived Suppressor Cells: Common Traits in Immune Regulation
Lyadova, I. V., Sosunova, E., Николаев, А. А., & Nenasheva, T. A. (2016) · Journal of Immunology Research · doi:10.1155/2016/7121580 · Cited by 31
“This suppresses cell proliferation, induces alternative macrophages (M2), stimulates Th2, and weakens Th1 responses [44–47].”
Tesařová, L., Jaresova, K., Šimara, P., & Koutná, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155366 · Cited by 29
Tu, C., Wang, Z., Xiang, E., Zhang, Q., Zhang, Y., Wu, P., Li, C., & Wu, D. (2022) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x17666220127110332 · Cited by 30
Chen, Y., Song, Y., Miao, H., Xu, Y., Lv, M., Wang, T., & Hou, Y. (2015) · Inflammation Research · doi:10.1007/s00011-015-0845-6 · Cited by 28
“It shows that IFN-c-licensed MSCs up-regulate IDO expression and activation, suppress T cell proliferation and effector function, but the suppression of T cell effector function by IFN-c-licensed MSCs is independent of IDO.”
Lin, F., Ichim, T. E., Pingle, S. C., Jones, L. D., Kesari, S., & Ashili, S. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i10.1067 · Cited by 27
Immunomodulation of endothelial differentiated mesenchymal stromal cells: impact on T and NK cells
Omar, R. E., Xiong, Y., Dostert, G., Louis, H., Gentils, M., Menu, P., Stoltz, J., Velot, É., & Decot, V. (2015) · Immunology and Cell Biology · doi:10.1038/icb.2015.94 · Cited by 29
Yi, J., Chen, Z., Xu, F., Wang, Z., Zhang, A., Liu, T., Zhao, N., Xiong, Y., Jiang, G., Ma, J., et al. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800963 · Cited by 25
GVHD-derived plasma as a priming strategy of mesenchymal stem cells
Silva-Carvalho, A. É., Rodrigues, L. P., Schiavinato, J. L. D. S., Alborghetti, M. R., Bettarello, G., Simões, B. P., Neves, F. D. A. R., Panepucci, R. A., Carvalho, J. L., & Saldanha‐Araújo, F. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01659-x · Cited by 26
“The primer sequences were as follows: PDL-1 sense primer sequence, 5′-AAACAATTAGACCTGGCTG-3′; PDL-1 antisense primer sequence, 5′-TCTTACCACTCAGGACTTG-3′; COX-2 sense primer sequence, 5′-GAAGTTGGCAGCAA ATTGAGC-3′; COX-2 antisense primer sequence, 5′- TTCTCCTGTGAAGGCGATGA-3′; HGF sense primer sequence, 5′-CATGCTGGCCCTTA…”
BackgroundInfluentialWang, J., Liu, H., Yue, G., Deng, Y., Cai, W., & Xu, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15282 · Cited by 26
“13,14 Therefore, we hypothesized that MSCs regulate the Th17/Treg balance through the PD-1/PD-L1 pathway, thereby exerting a therapeutic effect in DKD models.”
BackgroundNeo, S. H., Her, Z., Othman, R. B., Tee, C. A., Ong, L. C., Wang, Y., Tan, I., Tan, J., Yang, Y., Yang, Z., et al. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03481-7 · Cited by 27
“Currently, priming MSCs with pro-inflammatory cytokines including TNF-α [25] and IFN-ɣ [26, 27] are used to improve their ability to suppress T cells and reduce inflammation.”
MethodInflammatory niche: Mesenchymal stromal cell priming by soluble mediators
Jauković, A., Кукољ, Т., Obradović, H., Djordjević, I. O., Mojsilović, S. B., & Bugarski, D. S. (2020) · World Journal of Stem Cells · doi:10.4252/wjsc.v12.i9.922 · Cited by 29
Chemokine Assay Matrix Defines the Potency of Human Bone Marrow Mesenchymal Stromal Cells
Lipat, A. J., Cottle, C., Pirlot, B. M., Mitchell, J. M., Pando, B., Helmly, B., Kosko, J., Rajan, D., Hematti, P., & Chinnadurai, R. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac050 · Cited by 28
Self-citationPhinney, D. G., Lee, R. H., & Boregowda, S. V. (2023) · Stem Cells · doi:10.1093/stmcls/sxad019 · Cited by 28
Progress and Challenges of Amniotic Fluid Derived Stem Cells in Therapy of Ischemic Heart Disease
Fang, Y., Wang, S. P. H., Chang, H., Yang, P.-J., Liu, P., & Liu, Y.-W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010102 · Cited by 25
“They secrete many biologically active molecules, including cytokines, growth factors, and chemokines and regulate the activity of immune cells such as B cells, T cells, dendritic cells (DC), natural killer (NK) cells, neutrophils, and macrophages through autocrine and paracrine effects [5,6].”
BackgroundHealing the cornea: Exploring the therapeutic solutions offered by MSCs and MSC-derived EVs
Jammes, M., Tabasi, A., Bach, T., & Ritter, T. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101325 · Cited by 29
“Considered as the gold standard in pro-inflammatory licensing, priming MSCs with IFN-γ can induce expression of IDO and PD-L1 in MSCs, both of which play important roles in immunoregulation (Chinnadurai et al., 2014; Davies et al., 2017; Kim et al., 2018; Bulati et al., 2020).”
Kariminia, A., Ivison, S. M., Ng, B., Rozmus, J., Sung, S., Varshney, A., Aljurf, M. D., Lachance, S., Walker, I., Toze, C., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.170928 · Cited by 24
“Recipient median age (range) 43 (16 – 63) 46 (16 – 64) 48 (20-63) 46 (16-64) 49 (22-63) 47 (17-59)”
InfluentialTranslating MSC Therapy in the Age of Obesity
Boland, L. K., Bitterlich, L., Hogan, A. E., Ankrum, J. A., & English, K. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943333 · Cited by 31
“Furthermore, Wang et al. showed higher rates of circulating T cells with an exhausted profile (PD1+ with low proliferative rate) in obese, otherwise healthy patients (10).”
BackgroundInfluentialMancheño‐Corvo, P., Menta, R., del Río, B., Franquesa, M., Ramírez, C., Hoogduijn, M. J., DelaRosa, O., Dalemans, W., & Lombardo, E. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0508 · Cited by 25
“The authors and others have reported that the licensing effects of IFN-g are mediated through both IDO-dependent and IDO-indepen-dent mechanisms [17,20,21,30,31].”
Fine-tuning licensing strategies to boost MSC-based immunomodulatory secretome
Rossello-Gelabert, M., Igartua, M., Santos‐Vizcaíno, E., & Hernández, R. M. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04315-4 · Cited by 30
“While previous studies have explored cytokine licensing, few have systematically examined how variations in these parameters influence the quality and potency of the resulting secretome [18, 23–25, 27– 30, 33–36].”
InfluentialHuman Graft-Derived Mesenchymal Stromal Cells Potently Suppress Alloreactive T-Cell Responses
de Mare-Bredemeijer, E., Mancham, S., Verstegen, M. M. A., de Ruiter, P. E., van Gent, R., O’Neill, D. W., Tilanus, H. W., Metselaar, H. J., de Jonge, J., Kwekkeboom, J., et al. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0485 · Cited by 24
CD317-Positive Immune Stromal Cells in Human “Mesenchymal Stem Cell” Populations
Kay, A. G., Fox, J. M., Hewitson, J. P., Stone, A. P., Robertson, S., James, S. R., Wang, X., Kapasa, E., Yang, X., & Genever, P. G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.903796 · Cited by 20
Stenger, E. O., Giver, C. R., Langston, A. A., Kota, D. J., Das, P. K., Chinnadurai, R., Galipeau, J., Waller, E. K., & Qayed, M. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.959658 · Cited by 21
“priming during culture recovery, based on preclinical studies demonstrating enhanced potency (NCT04328714) (10, 26, 27).”
BackgroundSelf-citationVaillant, L., Akhter, W., Nakhle, J., Simon, M., Villalba, M., Jørgensen, C., Vignais, M., & Hernández, J. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03980-1 · Cited by 25
Immunomodulatory function of mesenchymal stem cells: regulation and application
Qu, G., Xie, X., Li, X., Chen, Y., de Isla, N., Huselstein, C., Stoltz, J., & Li, Y. (2018) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2018.09.001 · Cited by 23
The Dual Role of Mesenchymal Stromal Cells and Their Extracellular Vesicles in Carcinogenesis
Gilazieva, Z., Ponomarev, A. S., Rizvanov, A. A., & Solovyeva, V. V. (2022) · Biology · doi:10.3390/biology11060813 · Cited by 21
Barnhoorn, M. C., Jong, A. E. V. D. M., Schrama, E., Plug, L. G., Verspaget, H. W., Fibbe, W. E., van Pel, M., Hawinkels, L. J. A. C., & Schepers, K. (2022) · Stem Cells Translational Medicine · doi:10.1093/stcltm/szac054 · Cited by 23
Xu, F., Yi, J., Wang, Z., Hu, Y., Han, C., Xue, Q., Zhang, X., & Luan, X. (2017) · Immunologic Research · doi:10.1007/s12026-017-8929-8 · Cited by 20
Valencia, J., Yáñez, R. M., Muntión, S., Fernández-García, M., Martin-Rufino, J. D., Zapata, A. G., Bueren, J. A., Vicente, Á., & Sanchez-Guijo, F. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1473788 · Cited by 28
Svalgaard, J. D., Munthe‐Fog, L., Rivera‐Ballesteros, O., Brooks, P. T., Rangatchew, F., Vester-Glowinski, P. V., Haastrup, E. K., & Fischer‐Nielsen, A. (2020) · Cryobiology · doi:10.1016/j.cryobiol.2020.05.014 · Cited by 19
“We also investigated IFN-ɣ -mediated induction of PDL1 and PDL2, which are two ligands known to be involved in the cell contact-dependent immunosuppressive function of ASCs [21,22].”
Multipotent Stromal Cells and Viral Interaction: Current Implications for Therapy
Taechangam, N., Kol, A., Arzi, B., & Borjesson, D. L. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10224-9 · Cited by 23
“With CD8 + T-cells, it is well established that MSCs can inhibit T-cell proliferation [58, 59] through the release”
BackgroundImmunomodulatory Actions of Mesenchymal Stromal Cells (MSCs) in Osteoarthritis of the Knee
Babu, G. S., Badrish, Y., Oswal, V. M., Jeyaraman, N., Prajwal, G. S., Jeyaraman, M., Muthu, S., & Khanna, M. (2021) · Osteology · doi:10.3390/osteology1040020 · Cited by 21
Lopes‐Pacheco, M., & Rocco, P. R. M. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1067422 · Cited by 20
“IFNγ-preconditioned BM-MSCs were also effective at inhibiting T cell proliferation and subsequent secretion of TH1 cytokines by upregulating programmed cell death-1 ligands (PDL-1), regardless of IDO upregulation (Chinnadurai et al., 2014).”
BackgroundEvaluation of Immunomodulatory Properties of Feline Mesenchymal Stem Cells
Parys, M., Kruger, J. M., & Yuzbasiyan‐Gurkan, V. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0041 · Cited by 20
Voisin, C., Cauchois, G., Reppel, L., Laroye, C., Louarn, L., Schenowitz, C., Sonon, P., Poras, I., Wang, V., Carosella, E. D., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020423 · Cited by 20
“In contrast, it has been reported that primed MSCs with IFN-γ and/or TNF-α enhance the expression of MHC-II but do not seem to increase the levels of CD80 and CD86 [32].”
BackgroundInfluentialStenger, E. O., Chinnadurai, R., Yuan, S., Garcia, M. A., Arafat, D., Gibson, G. C., Krishnamurti, L., & Galipeau, J. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.01.081 · Cited by 23
“As IFN-γ -stimulated MSCs have augmented immunomodulatory function upon upregulation of IDO and MSC responsiveness to IFN-γ is a surrogate measure of potency, 21 we next compared IDO gene expression in MSCs ±IFN-γ .”
Self-citationZhang, S., Ren, J.-Y., & Yang, B. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i11.1625 · Cited by 21
Mesenchymal Stromal Cell Therapy in Hematology: From Laboratory to Clinic and Back Again
Becker, A. D., & Riet, I. V. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0564 · Cited by 21
“The same group also described an IDO independent pathway of immunosuppression by IFN-g -ac- tivated MSCs through the ligands of PD1 [50–52].”
Foreskin as a Source of Immunotherapeutic Mesenchymal Stromal Cells
Najar, M., & Lagneaux, L. (2017) · Immunotherapy · doi:10.2217/imt-2016-0093 · Cited by 19
Priyadarshani, P., Grouw, A. V., Liversage, A. R., Rui, K., Nikitina, A. A., Tehrani, K. F., Aggarwal, B., Stice, S. L., Sinha, S., Kemp, M. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114579 · Cited by 16
Comparative Approach to the Temporo-Spatial Organization of the Tumor Microenvironment
Langsten, K. L., Kim, J. H., Sarver, A. L., Dewhirst, M. W., & Modiano, J. F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01185 · Cited by 21
“Paradoxically, these cells can inhibit TNFα and IFNγ which are initially necessary for licensing or “tumor-mediated education,” while also increasing IL-10, an immunosuppressive cytokine (164).”
BackgroundInfluentialThej, C., Balasubramanian, S., Rengasamy, M., Walvekar, A., Swamynathan, P., Raj, S. S., Shahani, P., SiddikUzzaman, B. S. P., Kolkundkar, U., Seetharam, R. N., et al. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02330-9 · Cited by 18
Chinnadurai, R., Bates, P. D., Kunugi, K. A., Nickel, K. P., DeWerd, L. A., Capitini, C. M., Galipeau, J., & Kimple, R. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708950 · Cited by 17
Self-citationJuhl, M., Follin, B., Gad, M., Larsen, J., Kastrup, J., & Ekblond, A. (2020) · Stem Cells International · doi:10.1155/2020/8868909 · Cited by 8
“An often-highlighted immunosuppressive factor derived from ASC is IDO [20, 23, 24].”
BackgroundTian, L., Li, X., Guo, L., Huang, L., Wu, X., & Gao, W. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216027 · Cited by 16
Siemionow, M., Szilagyi, E., Cwykiel, J. M., Domaszewska-Szostek, A., Heydemann, A., Garcia-Martinez, J., & Siemionow, K. B. (2020) · Stem Cells and Development · doi:10.1089/scd.2020.0161 · Cited by 16
Park, H. Y., Kim, C. E., Lee, S.-M., Ahn, J. M., Yoon, E. H., Yoo, M., Kim, J., Back, J., Park, D. H., Jang, W. H., et al. (2022) · Stem Cells · doi:10.1093/stmcls/sxac075 · Cited by 18
Liver Disease and Cell Therapy: Advances Made and Remaining Challenges
Khan, S., Mahgoub, S., Fallatah, N. A., Lalor, P. F., & Newsome, P. N. (2023) · Stem Cells · doi:10.1093/stmcls/sxad029 · Cited by 18
“Agents tested to date include the use of cytokines or growth factors such as TNF-γ , IL-β 1, TNF α , IL-17, TGF β -1 199-202 as well as hypoxic culture conditions, 135,203 modification of culture methods 204 and genetic modification of MSC 205 to improve potency.”
MethodYang, H., Berezowska, S., Dorn, P., Zens, P., Chen, P., Peng, R., Marti, T. M., Kocher, G. J., Schmid, R. A., & Hall, S. R. R. (2021) · Theranostics · doi:10.7150/thno.61209 · Cited by 15
“for the immunosuppressive function of IFNγ-primed mesenchymal stromal cells [49].”
BackgroundReprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies
Faraj, J. A., Al-Athari, A. J. H., Mohie, S. E. D., Kadhim, I. K., Jawad, N. M., Abbas, W. J., & Jalil, A. T. (2022) · Medical Oncology · doi:10.1007/s12032-022-01842-5 · Cited by 19
Conklin, L. S., Hanley, P. J., Galipeau, J., Barrett, J. A., & Bollard, C. M. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.03.006 · Cited by 14
Self-citationHan, B. L., Zhou, L., Guan, Q., da Roza, G., Wang, H., & Du, C. (2018) · Stem Cells International · doi:10.1155/2018/5868745 · Cited by 14
High‐Throughput On‐Chip Human Mesenchymal Stromal Cell Potency Prediction
Schneider, R. S., Vela, A. C., Williams, E. K., Martin, K. E., Lam, W. A., & García, A. J. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101995 · Cited by 14
The effects of mesenchymal stem cells on the chemotherapy of colorectal cancer
Wang, M., Li, J., Wang, D., Xin, Y., & Liu, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114373 · Cited by 15
Zielniok, K., Burdzińska, A., Kaleta, B., Zagożdżon, R., & Pączek, L. (2020) · Cells · doi:10.3390/cells9112396 · Cited by 14
“It is known that licensing of MSCs with proinflammatory cytokines (IFNγ, TNFα) increases the expression of PD-L1 and PD-L2 on their cell surfaces [44,45].”
BackgroundTynecka, M., Moniuszko, M., & Eljaszewicz, A. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10137-7 · Cited by 13
“In the presence of IFNγ, MSCs release high amounts of IDO, which metabolizes the degradation of tryptophan to toxic catabolites accumulation, namely kynurenine, L-tryptophan, kynurenic acid, quinolinic acid, and anthranilic acid [122].”
BackgroundKuçi, Z., Piede, N., Vogelsang, K., Pfeffermann, L., Wehner, S., Salzmann‐Manrique, E., Stais, M., Kreyenberg, H., Bonig, H. B., Bader, P., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04684-5 · Cited by 16
Stenger, E. O., Krishnamurti, L., & Galipeau, J. (2015) · BMC Immunology · doi:10.1186/s12865-015-0135-7 · Cited by 12
Self-citationComputational study on new natural compound inhibitors of indoleamine 2,3-dioxygenase 1
Jiang, S., Li, H., Piao, L., Jin, Z. G., Liu, J., Chen, S., Liu, L. L., Shao, Y., Zhong, S., Wu, B., et al. (2020) · Aging · doi:10.18632/aging.103113 · Cited by 12
Zorzópulos, J., Opal, S. M., Hernando-Insúa, A., Rodriguez, J. M., Elías, F., Fló, J., López, R. A., Chasseing, N. A., Lux-Lantos, V. A., Coronel, M. F., et al. (2017) · World Journal of Stem Cells · doi:10.4252/wjsc.v9.i3.45 · Cited by 13
Menstrual Blood-Derived Stromal Stem Cells Augment CD4+ T Cells Proliferation.
Aleahmad, M., Ghanavatinejad, A., Bozorgmehr, M., Shokri, M.-R., Nikoo, S., Tavakoli, M., Kazemnejad, S., Shokri, F., & Zarnani, A. (2018) · Avicenna Journal of Medical Biotechnology · Cited by 12
Emerging trends in chromatin remodeler plasticity in mesenchymal stromal cell function
Chakraborty, S., Sinha, S., & Sengupta, A. (2020) · The FASEB Journal · doi:10.1096/fj.202002232r · Cited by 12
Uwazie, C. C., Pirlot, B. M., Faircloth, T. U., Patel, M., Parr, R. N., Zastre, H. M., Hematti, P., Moll, G., Rajan, D., & Chinnadurai, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1214098 · Cited by 10
“Consistent with previous publications, our results also demonstrate that IFNg upregulates both MHC Class I and MHC class II molecules on MSCs (55).”
ResultSelf-citationKawasaki, Y., Sato, K., Mashima, K., Nakano, H., Ikeda, T., Umino, K., Morita, K., Izawa, J., Takayama, N., Hayakawa, H., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2020.11.012 · Cited by 10
Lefevre, C., Chartoire, D., Ferraz, J. C., Verdier, T., Pinteur, C., Chanon, S., Pesenti, S., Vieille‐Marchiset, A., Genestier, L., Vidal, H., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202002046rr · Cited by 13
Galipeau, J. (2016) · Stem Cells · doi:10.1002/stem.2526 · Cited by 10
Self-citationMyocardial Cell Signaling During the Transition to Heart Failure
Zeglinski, M. R., Moghadam, A. R., Ande, S. R., Sheikholeslami, K., Mokarram, P., Sepehri, Z., Rokni, H., Mohtaram, N. K., Poorebrahim, M., Masoom, A., et al. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170053 · Cited by 13
Hypoxia and interleukin-1-primed mesenchymal stem/stromal cells as novel therapy for stroke
Salaudeen, M. A., Allan, S. M., & Pinteaux, E. (2023) · Human Cell · doi:10.1007/s13577-023-00997-1 · Cited by 10
“For instance, IFN-ɣ was able to re-establish the immunosuppressive activity of senescent MSCs without upregulating HLA-DR expression [109].”
BackgroundSinghatanadgit, W., Kitpakornsanti, S., Toso, M., & Pavasant, P. (2022) · Royal Society Open Science · doi:10.1098/rsos.220056 · Cited by 8
Modiano, J. F., Lindborg, B. A., McElmurry, R. T., Lewellen, M., Forster, C. L., Zamora, E. A., Schaack, J. B., Bellgrau, D., O’Brien, T. D., & Tolar, J. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1749-6 · Cited by 9
Jang, I. K., Jung, H. J., Noh, O. K., Lee, D., Lee, K., & Park, J. E. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9102 · Cited by 9
“These licensed MSCs inhibit the immune function of T cells through cell-to-cell direct contact and through the production of soluble factors including IDO (17).”
Park, K., Hwang, C. J., Yun, H., Yeo, I. J., Choi, D., Park, P., Kim, H., Lee, J. T., Jung, Y. S., Han, S., et al. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-01590-1 · Cited by 8
Ontoria‐Oviedo, I., Palacios, I., Panadero, J., Sanchez, B., Garcia‐García, F., López‐Cerdán, A., Dorronsoro, A., Castellano, D., Rodrı́guez-Borlado, L., Bernad, A., et al. (2020) · Stem Cells International · doi:10.1155/2020/8872009 · Cited by 8
“Some proteins identi fi ed in the plasmatic membrane of BM-MSCs including integrin α V, β 1, α 11, and α 5 act as adhesion molecules [44].”
Differential Phase Contrast Imaging to Predict MSC Immune Function
Rui, K., Priyadarshani, P., Liversage, A. R., Muñoz, C., Stice, S. L., & Mortensen, L. J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202501553 · Cited by 8
Recovery and maintenance of NESTIN expression in umbilical cord-MSC using a novel culture medium
Liu, Y., Xiao, F., Hu, X., Tang, Z., Fu, Z., Liang, X., Zeng, G., Zeng, W., Liao, Y., Ren, Y., et al. (2020) · AMB Express · doi:10.1186/s13568-020-01067-7 · Cited by 7
Metadata
- Authors
- Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J.
- Affiliations
- Emory University (US)
- Corresponding author
- Chinnadurai, Raghavan
- Galipeau, Jacques
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02
- Volume
- 192
- Issue
- 4
- Pages
- 1491-1501
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147854121
- Cited by
- 266
- References
- 63
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 15 · 2023: 30 · 2022: 15 · 2021: 28 · 2020: 31 · 2019: 19 · 2018: 22 · 2017: 25 · 2016: 24 · 2015: 21 · 2014: 10
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (T32AI007610)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- mesenchymal stem cells, T cell effector function, PD-L1, PD-1, T cell degranulation, interleukin-2, T cell proliferation inhibition, bone marrow-derived stromal cells
- MeSH terms
- Bone Marrow Cells, Cells, Cultured, Humans, Interferon-gamma, Interleukin-2, Lymphocyte Activation, Tumor Necrosis Factor-alpha, Cell Degranulation, Th1 Cells, RNA Interference, RNA, Small Interfering, Cell Proliferation, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mesenchymal Stem Cells, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.